@article{TLCR27724,
author = {Alfredo Addeo and Glen J. Weiss},
title = {Measuring tumor mutation burden in cell-free DNA: advantages and limits},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {The treatment for advanced non-small cell lung cancer (NSCLC) has changed rapidly over the last several years. There are now several commercially available checkpoint inhibitors (CPI) targeting the programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) pathway. These CPIs have been shown to confer a significant overall survival (OS) benefit in first- and second-line therapy for unresectable/metastatic NSCLC (1-5). While the use of CPI in the clinic is prevalent, the determinants of those most likely to benefit remains imprecise.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/27724}
}